Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide for cognitive function in obese bipolar disorder patients
NCT06331286Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of dulaglutide biosimilar 14028 injection in obesity and cognitive impairment (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Body Weight at 24 weeks, Concentration of blood glucose at 24 weeks and 5 more. Status: unknown.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
obesitycognitive impairment
Beyond the preview
Go deeper on NCT06331286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331286.